Complex adaptive immunity to enteric fevers in humans: Lessons learned and the path forward

Frontiers in Immunology

Volumn 5, Issue OCT, 2014, Pages

  Sztein, Marcelo B ^a   Salerno Goncalves, Rosangela ^a   McArthur, Monica A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

CMI; Enteric fever; Human immunity; Microbiota; Multifunctional t cells; Salmonella paratyphi; Salmonella typhi; Typhoid fever

Indexed keywords

ALVIRCEPT SUDOTOX; CD4 ANTIBODY; CHLORAMPHENICOL; GAMMA INTERFERON; HEPATITIS VACCINE; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OKT 8; TUMOR NECROSIS FACTOR ALPHA; TYPHOID VACCINE;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; CD8+ T LYMPHOCYTE; CELL HOMING; CELLULAR IMMUNITY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; HEPATITIS; HEPATOSPLENOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MICROFLORA; PARATYPHOID FEVER; PROTEIN PHOSPHORYLATION; RETICULOENDOTHELIAL SYSTEM; REVIEW; SALMONELLA PARATYPHI; SALMONELLA PARATYPHI B; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; STREPTOCOCCUS PNEUMONIAE; TYPHOID FEVER;

EID: 84918788980     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00516     Document Type: Review

References (232)

1. Levine MM. Typhoid vaccines ready for implementation. N Engl J Med (2009) 361(4):403-5. doi: 10.1056/NEJMe0905519
2. Sahastrabuddhe S, Carbis R, Wierzba TF, Ochiai RL. Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development. Expert Rev Vaccines (2013) 12(9):1021-31. doi:10.1586/14760584.2013.825450
3. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin Infect Dis (2007) 45(Suppl 1):S24-8. doi:10.1086/518141
4. Alam MM, Tsai LL, Rollins SM, Sheikh A, Khanam F, Bufano MK, et al. Identification of in vivo-induced bacterial proteins during human infection with Salmonella enterica serotype Paratyphi A. Clin Vaccine Immunol (2013) 20(5):712-9. doi:10.1128/cvi.00054-13
5. Arndt MB, Mosites EM, Tian M, Forouzanfar MH, Mokhdad AH, Meller M, et al. Estimating the burden of paratyphoid a in Asia and Africa. PLoS Negl Trop Dis (2014) 8(6):e2925. doi:10.1371/journal.pntd.0002925
6. Gal-Mor O, Suez J, Elhadad D, Porwollik S, Leshem E, Valinsky L, et al. Molecular and cellular characterization of a Salmonella enterica serovar Paratyphi a outbreak strain and the human immune response to infection. Clin Vaccine Immunol (2012) 19(2):146-56. doi:10.1128/cvi.05468-11
7. Teh CS, Chua KH, Thong KL. Paratyphoid fever: splicing the global analyses. Int J Med Sci (2014) 11(7):732-41. doi:10.7150/ijms.7768
8. Levine MM. Typhoid fever vaccines. In: Plotkin SA, Mortimer EA, editors. Vaccines. Philadelphia, PA: W.B. Saunders Company (1994). p. 597-633.
9. Paterson GK, Maskell DJ. Recent advances in the field of Salmonella typhi vaccines. Hum Vaccin (2010) 6(5):379-84. doi:10.4161/hv.6.5.10755
10. Buckle GC, Walker CL, Black RE. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Global Health (2012) 2(1):010401. doi:10.7189/jogh.02.010401
11. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ (2004) 82(5):346-53.
12. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull World Health Organ (1994) 72(6):957-71.
13. Levine MM, Levine OS. Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use. Lancet (1997) 350(9088):1386-92. doi:10.1016/S0140-6736(97)03253-4
14. DeRoeck D, Jodar L, Clemens J. Putting typhoid vaccination on the global health agenda. N Engl J Med (2007) 357(11):1069-71. doi:10.1056/NEJMp078144
15. Connerton P, Wain J, Hien TT, Ali T, Parry C, Chinh NT, et al. Epidemic typhoid in Vietnam: molecular typing of multiple-antibiotic-resistant Salmonella enterica serotype Typhi from four outbreaks. J Clin Microbiol (2000) 38(2):895-7.
16. Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis (1997) 24(Suppl 1):S106-9. doi:10.1093/clinids/24.Supplement_1.S106
17. Petri WA Jr, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections, diarrhea, and their impact on function and development. J Clin Invest (2008) 118(4):1277-90. doi:10.1172/jci34005
18. Levine MM, Sztein MB. Human mucosal vaccines for Salmonella typhi infections. In: Kiyono H, Ogra PL, McGhee JR, editors. Mucosal Vaccines. SanDiego, CA: Academic Press (1996). p. 201-11.
19. Stuart BM, Pullen RL. Typhoid; clinical analysis of 360 cases. Arch Intern Med (Chic) (1946) 78(6):629-61. doi:10.1001/archinte.1946.00220060002001
20. Mastroeni P, Menager N. Development of acquired immunity to Salmonella. J Med Microbiol (2003) 52(Pt 6):453-9. doi:10.1099/jmm.0.05173-0
21. Dougan G, John V, Palmer S, Mastroeni P. Immunity to salmonellosis. Immunol Rev (2011) 240(1):196-210. doi:10.1111/j.1600-065X.2010.00999.x
22. Marmion DE, Naylor GR, Stewart IO. Second attacks of typhoid fever. J Hyg (Lond) (1953) 51(2):260-7. doi:10.1017/S0022172400015680
23. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ. Typhoid fever: pathogenesis and immunologic control. N Engl J Med (1970) 283(13):686-91. doi:10.1056/NEJM197009242831306
24. Tang SW, Abubakar S, Devi S, Puthucheary S, Pang T. Induction and characterization of heat shock proteins of Salmonella typhi and their reactivity with sera from patients with typhoid fever. Infect Immun (1997) 65(7):2983-6.
25. Calderon I, Lobos SR, Rojas HA, Palomino C, Rodriguez LH, Mora GC. Antibodies to porin antigens of Salmonella typhi induced during typhoid infection in humans. Infect Immun (1986) 52(1):209-12.
26. Herath HM. Early diagnosis of typhoid fever by the detection of salivary IgA. J Clin Pathol (2003) 56(9):694-8. doi:10.1136/jcp.56.9.694
27. Jesudason MV, Sridharan G, Arulselvan R, Babu PG, John TJ. Diagnosis of typhoid fever by the detection of anti-LPS & anti-flagellin antibodies by ELISA. Indian J Med Res (1998) 107:204-7.
28. Ortiz V, Isibasi A, Garcia-Ortigoza E, Kumate J. Immunoblot detection of class-specific humoral immune response to outer membrane proteins isolated from Salmonella typhi in humans with typhoid fever. J Clin Microbiol (1989) 27(7):1640-5.
29. Levine MM, Grados O, Gilman RH, Woodward WE, Solis-Plaza R, Waldman W. Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg (1978) 27(4):795-800.
30. Losonsky GA, Ferreccio C, Kotloff KL, Kaintuck S, Robbins JB, Levine MM. Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers. J Clin Microbiol (1987) 25(12):2266-9.
31. Sheikh A, Bhuiyan MS, Khanam F, Chowdhury F, Saha A, Ahmed D, et al. Salmonella enterica serovar Typhi-specific immunoglobulin A antibody responses in plasma and antibody in lymphocyte supernatant specimens in Bangladeshi patients with suspected typhoid fever. Clin Vaccine Immunol (2009) 16(11):1587-94. doi:10.1128/CVI.00311-09
32. Sarasombath S, Banchuin N, Sukosol T, Rungpitarangsi B, Manasatit S. Systemic and intestinal immunities after natural typhoid infection. J Clin Microbiol (1987) 25(6):1088-93.
33. Pulickal AS, Gautam S, Clutterbuck EA, Thorson S, Basynat B, Adhikari N, et al. Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal. Clin Vaccine Immunol (2009) 16(10):1413-9. doi:10.1128/CVI.00245-09
34. Dupont HL, Hornick RB, Snyder MJ, Dawkins AT, Heiner GG, Woodward TE. Studies of immunity in typhoid fever. Protection induced by killed oral antigens or by primary infection. Bull World Health Organ (1971) 44(5):667-72.
35. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science (1998) 280(5368):1435-8. doi:10.1126/science.280.5368.1435
36. Gordon MA. Salmonella infections in immunocompromised adults. J Infect (2008) 56(6):413-22. doi:10.1016/j.jinf.2008.03.012
37. Lammas DA, Casanova JL, Kumararatne DS. Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway. Clin Exp Immunol (2000) 121(3):417-25. doi:10.1046/j.1365-2249.2000.01284.x
38. MacLennan C, Fieschi C, Lammas DA, Picard C, Dorman SE, Sanal O, et al. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis (2004) 190(10):1755-7. doi:10.1086/425021
39. Dunstan SJ, Stephens HA, Blackwell JM, Duc CM, Lanh MN, Dudbridge F, et al. Genes of the class II and class III major histocompatibility complex are associated with typhoid fever in Vietnam. J Infect Dis (2001) 183(2):261-8. doi:10.1086/317940
40. Gotuzzo E, Frisancho O, Sanchez J, Liendo G, Carrillo C, Black RE, et al. Association between the acquired immunodeficiency syndrome and infection with Salmonella typhi or Salmonella Paratyphi in an endemic typhoid area. Arch Intern Med (1991) 151(2):381-2. doi:10.1001/archinte.1991.00400020125026
41. Dham SK, Thompson RA. Humoral and cell-mediated immune responses in chronic typhoid carriers. Clin Exp Immunol (1982) 50(1):34-40.
42. Dham SK, Thompson RA. Studies of cellular and humoral immunity in typhoid fever and TAB vaccinated subjects. Clin Exp Immunol (1982) 48(2):389-95.
43. Espersen F, Mogensen HH, Hoiby N, Hoj L, Greibe J, Rasmussen SN, et al. Humoral and cellular immunity in typhoid and paratyphoid carrier state, investigated by means of quantitative immunoelectrophoresis and in vitro stimulation of blood lymphocytes. Acta Pathol Microbiol Immunol Scand C (1982) 90(6):293-9.
44. Murphy JR, Baqar S, Munoz C, Schlesinger L, Ferreccio C, Lindberg AA, et al. Characteristics of humoral and cellular immunity to Salmonella typhi in residents of typhoid-endemic and typhoid-free regions. J Infect Dis (1987) 156(6):1005-9. doi:10.1093/infdis/156.6.1005
45. Murphy JR, Wasserman SS, Baqar S, Schlesinger L, Ferreccio C, Lindberg AA, et al. Immunity to Salmonella typhi: considerations relevant to measurement of cellular immunity in typhoid-endemic regions. Clin Exp Immunol (1989) 75(2):228-33.
46. Rajagopalan P, Kumar R, Malaviya AN. Immunological studies in typhoid fever. II. Cell-mediated immune responses and lymphocyte subpopulations in patients with typhoid fever. Clin Exp Immunol (1982) 47(2):269-74.
47. Butler T, Ho M, Acharya G, Tiwari M, Gallati H. Interleukin-6, gamma interferon, and tumor necrosis factor receptors in typhoid fever related to outcome of antimicrobial therapy. Antimicrob Agents Chemother (1993) 37(11):2418-21. doi:10.1128/AAC.37.11.2418
48. Keuter M, Dharmana E, Gasem MH, van der Ven-Jongekrijg J, Djokomoeljanto R, Dolmans WM, et al. Patterns of proinflammatory cytokines and inhibitors during typhoid fever. J Infect Dis (1994) 169(6):1306-11. doi:10.1093/infdis/169.6.1306
49. Bhuiyan S, Sayeed A, Khanam F, Leung DT, Rahman Bhuiyan T, Sheikh A, et al. Cellular and cytokine responses to Salmonella enterica serotype Typhi proteins in patients with typhoid fever in Bangladesh. Am J Trop Med Hyg (2014) 90(6):1024-30. doi:10.4269/ajtmh.13-0261
50. Harris JB, Baresch-Bernal A, Rollins SM, Alam A, LaRocque RC, Bikowski M, et al. Identification of in vivo-induced bacterial protein antigens during human infection with Salmonella enterica serovar Typhi. Infect Immun (2006) 74(9):5161-8. doi:10.1128/iai.00488-06
51. Sheikh A, Khanam F, Sayeed MA, Rahman T, Pacek M, Hu Y, et al. Interferon-gamma and proliferation responses to Salmonella enterica serotype Typhi proteins in patients with S. Typhi bacteremia in Dhaka, Bangladesh. PLoS Negl Trop Dis (2011) 5(6):e1193. doi:10.1371/journal.pntd.0001193
52. Wyant TL, Tanner MK, Sztein MB. Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes. Infect Immun (1999) 67(7):3619-24.
53. Wyant TL, Tanner MK, Sztein MB. Potent immunoregulatory effects of Salmonella typhi flagella on antigenic stimulation of human peripheral blood mononuclear cells. Infect Immun (1999) 67(3):1338-46.
54. Ekpo P, Sarasombath S, Banchuin N, Pongsunk S, Korbsrisate S, Sirisinha S. Monoclonal antibodies against protein antigens of salmonellae causing paratyphoid fever and their diagnostic application. Asian Pac J Allergy Immunol (1995) 13(1):63-70.
55. Sheikh A, Charles RC, Rollins SM, Harris JB, Bhuiyan MS, Khanam F, et al. Analysis of Salmonella enterica serotype Paratyphi A gene expression in the blood of bacteremic patients in Bangladesh. PLoS Negl Trop Dis (2010) 4(12):e908. doi:10.1371/journal.pntd.0000908
56. Stoycheva M, Murdjeva M. Serum levels of interferon-gamma, interleukin-12, tumour necrosis factor-alpha, and interleukin-10, and bacterial clearance in patients with gastroenteric Salmonella infection. Scand J Infect Dis (2005) 37(1):11-4. doi:10.1080/00365540410026068
57. Pasetti MF, Levine MM, Sztein MB. Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine (2003) 21(5-6):401-18. doi:10.1016/S0264-410X(02)00472-3
58. de Jong HK, Parry CM, van der Poll T, Wiersinga WJ. Host-pathogen interaction in invasive salmonellosis. PLoS Pathog (2012) 8(10):e1002933. doi:10.1371/journal.ppat.1002933
59. Waddington CS, Darton TC, Woodward WE, Angus B, Levine MM, Pollard AJ. Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies. J Infect (2014) 68(5):405-18. doi:10.1016/j.jinf.2014.01.006
60. Darton TC, Blohmke CJ, Pollard AJ. Typhoid epidemiology, diagnostics and the human challenge model. Curr Opin Gastroenterol (2014) 30(1):7-17. doi:10.1097/mog.0000000000000021
61. Hornick RB, Woodward WE, Greisman SE. Doctor T. E. Woodward's legacy: from typhus to typhoid fever. Clin Infect Dis (2007) 45(Suppl 1):S6-8. doi:10.1086/518138
62. Greisman SE, Woodward TE, Hornick RB, Snyder MJ, Carozza FA Jr. Typhoid fever: a study of pathogenesis and physiologic abnormalities. Trans Am Clin Climatol Assoc (1961) 73:146-61.
63. Waddington CS, Darton TC, Jones C, Haworth K, Peters A, John T, et al. An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis (2014) 58(9):1230-40. doi:10.1093/cid/ciu078
64. DuPont HL, Hornick RB, Weiss CF, Snyder MJ, Woodward TE. Evaluation of chloramphenicol acid succinate therapy of induced typhoid fever and Rocky Mountain spotted fever. N Engl J Med (1970) 282(2):53-7. doi:10.1056/nejm197001082820201
65. Groschel DH, Hornick RB. Who introduced typhoid vaccination: Almroth Write or Richard Pfeiffer? Rev Infect Dis (1981) 3(6):1251-4. doi:10.1093/clinids/3.6.1251
66. Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud A, et al. Vaccines against typhoid fever. Vaccine (2006) 24(18):3804-11. doi:10.1016/j.vaccine.2005.07.111
67. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis (1989) 11(Suppl 3):S552-67. doi:10.1093/clinids/11.Supplement_3.S552
68. Ashcroft MT, Ritchie JM, Nicholson CC, Stuart CA. Antibody responses to vaccination of british guyana schoolchildren with heat-killed-phenolized and acetone-killed lyophilized typhoid vaccines. Am J Hyg (1964) 80:221-8.
69. Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med (2009) 361(4):335-44. doi:10.1056/NEJMoa0807521
70. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine (1999) 17(Suppl 2):S22-7. doi:10.1016/S0264-410X(99)00231-5
71. Marathe SA, Lahiri A, Negi VD, Chakravortty D. Typhoid fever & vaccine development: a partially answered question. Indian J Med Res (2012) 135:161-9.
72. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine (1996) 14(5):435-8. doi:10.1016/0264-410X(95)00186-5
73. Sabitha P, Prabha Adhikari MR, Chowdary A, Prabhu M, Soofi M, Shetty M, et al. Comparison of the immunogenicity and safety of two different brands of Salmonella typhi Vi capsular polysaccharide vaccine. Indian J Med Sci (2004) 58(4):141-9.
74. Azze RF, Rodriguez JC, Iniesta MG, Marchena XR, Alfonso VM, Padron FT. Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine -vax-TyVi -in Cuban school children and teenagers. Vaccine (2003) 21(21-22):2758-60. doi:10.1016/S0264-410X(03)00177-4
75. Beeching NJ, Clarke PD, Kitchin NR, Pirmohamed J, Veitch K, Weber F. Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine (2004) 23(1):29-35. doi:10.1016/j.vaccine.2004.05.040
76. Yang HH, Kilgore PE, Yang LH, Park JK, Pan YF, Kim Y, et al. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis (2001) 183(12):1775-80. doi:10.1086/320729
77. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis (1989) 159(4):766-9. doi:10.1093/infdis/159.4.766
78. Forrest BD. Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine. Infect Immun (1992) 60(5):2023-9.
79. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine (1990) 8(4):321-6. doi:10.1016/0264-410X(90)90088-4
80. Lundgren A, Kaim J, Jertborn M. Parallel analysis of mucosally derived B-and T-cell responses to an oral typhoid vaccine using simplified methods. Vaccine (2009) 27(33):4529-36. doi:10.1016/j.vaccine.2009.05.005
81. Lundin BS, Johansson C, Svennerholm AM. Oral immunization with a Salmonella enterica serovar Typhi vaccine induces specific circulating mucosa-homing CD4(+) and CD8(+) T cells in humans. Infect Immun (2002) 70(10):5622-7. doi:10.1128/IAI.70.10.5622-5627.2002
82. Salerno-Goncalves R, Wahid R, Sztein MB. Ex vivo kinetics of early and long-term multifunctional human leukocyte antigen E-specific CD8+ cells in volunteers immunized with the Ty21a typhoid vaccine. Clin Vaccine Immunol (2010) 17(9):1305-14. doi:10.1128/CVI.00234-10
83. Salerno-Goncalves R, Wahid R, Sztein MB. Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires. Infect Immun (2005) 73(6):3521-30. doi:10.1128/IAI.73.6.3521-3530.2005
84. Salerno-Goncalves R, Pasetti MF, Sztein MB. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol (2002) 169(4):2196-203. doi:10.4049/jimmunol.169.4.2196
85. Salerno-Goncalves R, Fernandez-Vina M, Lewinsohn DM, Sztein MB. Identification of a human HLA-E-restricted CD8+ T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol (2004) 173(9):5852-62. doi:10.4049/jimmunol.173.9.5852
86. Tagliabue A, Nencioni L, Caffarena A, Villa L, Boraschi D, Cazzola G, et al. Cellular immunity against Salmonella typhi after live oral vaccine. Clin Exp Immunol (1985) 62:242-7.
87. Tagliabue A, Villa L, De Magistris MT, Romano M, Silvestri S, Boraschi D, et al. IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. J Immunol (1986) 137(5):1504-10.
88. Viret JF, Favre D, Wegmuller B, Herzog C, Que JU, Cryz SJ Jr, et al. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun (1999) 67(7):3680-5.
89. Wahid R, Pasetti MF, Maciel M Jr, Simon JK, Tacket CO, Levine MM, et al. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clin Immunol (2011) 138(2):187-200. doi:10.1016/j.clim.2010.11.006
90. Wahid R, Zafar SJ, McArthur MA, Pasetti MF, Levine MM, Sztein MB. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B. Clin Vaccine Immunol (2014) 21(3):427-34. doi:10.1128/cvi.00786-13
91. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol (2012) 19(6):825-34. doi:10.1128/CVI.00058-12
92. McArthur MA, Sztein MB. Heterogeneity of multifunctional IL-17A producing S. Typhi-specific CD8+ T cells in volunteers following Ty21a typhoid immunization. PloS One (2012) 7(6):e38408. doi:10.1371/journal.pone.0038408
93. Chinnasami B, Mangayarkarasi V, Prema A, Sadasivam K, Davis M. Safety and immunogenicity of Salmonella Typhi Vi conjugate vaccine (Peda Typh) in children up to five years. Int J Sci Res Publ (2013) 3(2):1-5.
94. Szu SC, Klugman KP, Hunt S. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children. Vaccine (2014) 32(20):2359-63. doi:10.1016/j.vaccine.2014.02.050
95. van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, et al. Safety, immunogenicity and dose ranging of a new Vi-CRM(1)(9)(7) conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One (2011) 6(9):e25398. doi:10.1371/journal.pone.0025398
96. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med (2001) 344(17):1263-9. doi:10.1056/nejm200104263441701
97. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med (2002) 347(22):1770-82. doi:10.1056/NEJMra020201
98. Thiem VD, Lin FY, Canh do G, Son NH, Anh DD, Mao ND, et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol (2011) 18(5):730-5. doi:10.1128/cvi.00532-10
99. Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2-to 5-year-old Vietnamese children. Infect Immun (2004) 72(11):6586-8. doi:10.1128/IAI.72.11.6586-6588.2004
100. Research ICoM. Clinical Trials Registry. National Institute of Medical Stetitstics (2014). Available from: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=4714&EncHid=&userName=Vi-TT
101. Simon R, Levine MM. Glycoconjugate vaccine strategies for protection against invasive Salmonella infections. Hum Vaccin Immunother (2012) 8(4):494-8. doi:10.4161/hv.19158
102. Cui C, Carbis R, An SJ, Jang H, Czerkinsky C, Szu SC, et al. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar Typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol (2010) 17(1):73-9. doi:10.1128/cvi.00266-09
103. Saha MR, Ramamurthy T, Dutta P, Mitra U. Emergence of Salmonella typhi Vi antigen-negative strains in an epidemic of multidrug-resistant typhoid fever cases in Calcutta, India. Natl Med J India (2000) 13(3):164.
104. Baker S, Sarwar Y, Aziz H, Haque A, Ali A, Dougan G, et al. Detection of Vi-negative Salmonella enterica serovar Typhi in the peripheral blood of patients with typhoid fever in the Faisalabad region of Pakistan. J Clin Microbiol (2005) 43(9):4418-25. doi:10.1128/jcm.43.9.4418-4425.2005
105. Tacket CO, Hone DM, Curtiss R III, Kelly SM, Losonsky G, Guers L, et al. Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun (1992) 60(2):536-41.
106. Hone DM, Tacket CO, Harris AM, Kay B, Losonsky G, Levine MM. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest (1992) 90(2):412-20.
107. Sztein MB, Wasserman SS, Tacket CO, Edelman R, Hone D, Lindberg AA, et al. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis (1994) 170(6):1508-17. doi:10.1093/infdis/170.6.1508
108. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine (1992) 10(7):443-6. doi:10.1016/0264-410X(92)90392-W
109. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis (2007) 45(Suppl 1):S20-3. doi:10.1086/518135
110. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 65(2):452-6.
111. Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant TL, Nataro J, et al. Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol (2000) 97(2):146-53. doi:10.1006/clim.2000.4924
112. Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis (2004) 190(3):565-70. doi:10.1086/421469
113. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis (1996) 173(6):1408-14. doi:10.1093/infdis/173.6.1408
114. Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis (2005) 192(3):360-6. doi:10.1086/431605
115. Kirkpatrick BD, Bentley MD, Thern AM, Larsson CJ, Ventrone C, Sreenivasan MV, et al. Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cell assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09). Clin Diagn Lab Immunol (2005) 12(9):1127-9.
116. Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, et al. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units. Vaccine (2010) 28(20):3602-8. doi:10.1016/j.vaccine.2010.02.017
117. Tran TH, Nguyen TD, Nguyen TT, Ninh TT, Tran NB, Nguyen VM, et al. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One (2010) 5(7):e11778. doi:10.1371/journal.pone.0011778
118. Lindow JC, Fimlaid KA, Bunn JY, Kirkpatrick BD. Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi. Infect Immun (2011) 79(8):3188-94. doi:10.1128/IAI.05081-11
119. Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA, et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun (2002) 70(7):3457-67. doi:10.1128/IAI.70.7.3457-3467.2002
120. Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine (2006) 24(2):116-23. doi:10.1016/j.vaccine.2005.08.008
121. Salerno-Goncalves R, Wyant TL, Pasetti MF, Fernandez-Vina M, Tacket CO, Levine MM, et al. Concomitant induction of CD4(+) and CD8(+) T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain CVD 908-htrA. J Immunol (2003) 170(5):2734-41. doi:10.4049/jimmunol.170.5.2734
122. Sztein MB, Tanner MK, Polotsky Y, Orenstein JM, Levine MM. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J Immunol (1995) 155(8):3987-93.
123. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine (2007) 25(8):1416-25. doi:10.1016/j.vaccine.2006.10.040
124. Roland KL, Tinge SA, Kochi SK, Thomas LJ, Killeen KP. Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates. Vaccine (2010) 28(21):3679-87. doi:10.1016/j.vaccine.2010.03.019
125. Gat O, Galen JE, Tennant S, Simon R, Blackwelder WC, Silverman DJ, et al. Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines. PLoS Negl Trop Dis (2011) 5(11):e1373. doi:10.1371/journal.pntd.0001373
126. Micoli F, Rondini S, Gavini M, Lanzilao L, Medaglini D, Saul A, et al. O:2-CRM(197) conjugates against Salmonella Paratyphi A. PLoS One (2012) 7(11):e47039. doi:10.1371/journal.pone.0047039
127. Galen JE, Pasetti MF, Tennant S, Ruiz-Olvera P, Sztein MB, Levine MM. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol (2009) 87(5):400-12. doi:10.1038/icb.2009.31
128. Frey SE, Lottenbach KR, Hill H, Blevins TP, Yu Y, Zhang Y, et al. A phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. Vaccine (2013) 31(42):4874-80. doi:10.1016/j.vaccine.2013.07.049
129. Gonzalez C, Hone D, Noriega FR, Tacket CO, Davis JR, Losonsky G, et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis (1994) 169(4):927-31. doi:10.1093/infdis/169.4.927
130. Khan S, Chatfield S, Stratford R, Bedwell J, Bentley M, Sulsh S, et al. Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans. Vaccine (2007) 25(21):4175-82. doi:10.1016/j.vaccine.2007.03.007
131. Nardelli-Haefliger D, Kraehenbuhl JP, Curtiss R III, Schodel F, Potts A, Kelly S, et al. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun (1996) 64(12):5219-24.
132. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine (1999) 18(5-6):449-59. doi:10.1016/S0264-410X(99)00246-7
133. Metzger WG, Mansouri E, Kronawitter M, Diescher S, Soerensen M, Hurwitz R, et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar Typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine (2004) 22(17-18):2273-7. doi:10.1016/j.vaccine.2003.11.020
134. Bumann D, Holland P, Siejak F, Koesling J, Sabarth N, Lamer S, et al. A Comparison of murine and human immunoproteomes of Helicobacter pylori validates the preclinical murine infection model for antigen screening. Infect Immun (2002) 70(11):6494-8. doi:10.1128/IAI.70.11.6494-6498.2002
135. Kilhamn J, Lundin SB, Brevinge H, Svennerholm AM, Jertborn M. T-and B-cell immune responses of patients who had undergone colectomies to oral administration of Salmonella enterica serovar Typhi Ty21a vaccine. Clin Diagn Lab Immunol (2003) 10(3):426-30.
136. Salazar-Gonzalez RM, Maldonado-Bernal C, Ramirez-Cruz NE, Rios-Sarabia N, Beltran-Nava J, Castanon-Gonzalez J, et al. Induction of cellular immune response and anti-Salmonella enterica serovar Typhi bactericidal antibodies in healthy volunteers by immunization with a vaccine candidate against typhoid fever. Immunol Lett (2004) 93(2-3):115-22. doi:10.1016/j.imlet.2004.01.010
137. Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev (2011) 239(1):125-48. doi:10.1111/j.1600-065X.2010.00970.x
138. Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis (2007) 45(Suppl 1):S15-9. doi:10.1086/518140
139. Tacket CO, Ferreccio C, Robbins JB, Tsai CM, Schulz D, Cadoz M, et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis (1986) 154(2):342-5. doi:10.1093/infdis/154.2.342
140. Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun (2000) 68(3):1196-201. doi:10.1128/IAI.68.3.1196-1201.2000
141. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ. Typhoid fever: pathogenesis and immunologic control. 2. N Engl J Med (1970) 283(14):739-46. doi:10.1056/NEJM197010012831406
142. Raffatellu M, Chessa D, Wilson RP, Tukel C, Akcelik M, Baumler AJ. Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis. Infect Immun (2006) 74(1):19-27. doi:10.1128/IAI.74.1.19-27.2006
143. Wangdi T, Lee CY, Spees AM, Yu C, Kingsbury DD, Winter SE, et al. The Vi capsular polysaccharide enables Salmonella enterica serovar Typhi to evade microbe-guided neutrophil chemotaxis. PLoS Pathog (2014) 10(8):e1004306. doi:10.1371/journal.ppat.1004306
144. Levine MM, Tacket CO, Sztein MB. Host-Salmonella interaction: human trials. Microbes Infect (2001) 3(14-15):1271-9. doi:10.1016/S1286-4579(01)01487-3
145. Cancellieri V, Fara GM. Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine. J Infect Dis (1985) 151(3):482-4. doi:10.1093/infdis/151.3.482
146. Pakkanen SH, Kantele JM, Moldoveanu Z, Hedges S, Hakkinen M, Mestecky J, et al. Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids. Clin Vaccine Immunol (2010) 17(3):393-401. doi:10.1128/CVI.00475-09
147. Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol (2010) 125(2 Suppl 2):S41-52. doi:10.1016/j.jaci.2009.09.046
148. Persson MA, Ekwall E, Hammarstrom L, Lindberg AA, Smith CI. Immunoglobulin G (IgG) and IgA subclass pattern of human antibodies to Shigella flexneri and Salmonella serogroup B and D lipopolysaccharide O antigens. Infect Immun (1986) 52(3):834-9.
149. Mittrucker HW, Raupach B, Kohler A, Kaufmann SH. Cutting edge: role of B lymphocytes in protective immunity against Salmonella typhimurium infection. J Immunol (2000) 164(4):1648-52. doi:10.4049/jimmunol.164.4.1648
150. de Wit J, Souwer Y, Jorritsma T, Klaasse Bos H, ten Brinke A, Neefjes J, et al. Antigen-specific B cells reactivate an effective cytotoxic T cell response against phagocytosed Salmonella through cross-presentation. PLoS One (2010) 5(9):e13016. doi:10.1371/journal.pone.0013016
151. Salerno-Goncalves R, Rezwan T, Sztein MB. B cells modulate mucosal associated invariant T cell immune responses. Front Immunol (2014) 4:511. doi:10.3389/fimmu.2013.00511
152. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Generation of specific effector and memory T cells with gut-and secondary lymphoid tissue-homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol (2008) 1(5):389-98. doi:10.1038/mi.2008.30
153. Tarlinton D, Radbruch A, Hiepe F, Dorner T. Plasma cell differentiation and survival. Curr Opin Immunol (2008) 20(2):162-9. doi:10.1016/j.coi.2008.03.016
154. Kantele A, Kantele JM, Savilahti E, Westerholm M, Arvilommi H, Lazarovits A, et al. Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. J Immunol (1997) 158(2):574-9.
155. Kantele A, Pakkanen SH, Karttunen R, Kantele JM. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines -a randomized trial. PLoS One (2013) 8(4):e60583. doi:10.1371/journal.pone.0060583
156. Penttila IA, Gibson CE, Leong AY, Zola H, LaBrooy JT. Cell surface determinants on typhoid-specific B cells isolated from peripheral blood after oral Ty21a typhoid vaccination in humans. Immunol Cell Biol (1995) 73(3):198-204. doi:10.1038/icb.1995.33
157. Kantele A, Westerholm M, Kantele JM, Makela PH, Savilahti E. Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans. Vaccine (1999) 17(3):229-36. doi:10.1016/S0264-410X(98)00193-5
158. Kantele A. Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine. J Biotechnol (1996) 44(1-3):217-24. doi:10.1016/0168-1656(95)00134-4
159. Kantele A, Arvilommi H, Kantele JM, Rintala L, Makela PH. Comparison of the human immune response to live oral, killed oral or killed parenteral Salmonella typhi TY21A vaccines. Microb Pathog (1991) 10(2):117-26. doi:10.1016/0882-4010(91)90072-I
160. Levine MM, Sztein MB. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol (2004) 5(5):460-4. doi:10.1038/ni0504-460
161. Takemori T, Kaji T, Takahashi Y, Shimoda M, Rajewsky K. Generation of memory B cells inside and outside germinal centers. Eur J Immunol (2014) 44(5):1258-64. doi:10.1002/eji.201343716
162. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol (2012) 12(3):191-200. doi:10.1038/nri3158
163. Tangye SG, Good KL. Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol (2007) 179(1):13-9. doi:10.4049/jimmunol.179.1.13
164. Perez-Shibayama C, Gil-Cruz C, Pastelin-Palacios R, Cervantes-Barragan L, Hisaki E, Chai Q, et al. IFN-gamma-producing CD4+ T cells promote generation of protective germinal center-derived IgM+ B cell memory against Salmonella Typhi. J Immunol (2014) 192(11):5192-200. doi:10.4049/jimmunol.1302526
165. Toapanta FR, Bernal PJ, Sztein MB. Diverse phosphorylation patterns of B cell receptor-associated signaling in naive and memory human B cells revealed by phosphoflow, a powerful technique to study signaling at the single cell level. Front Cell Infect Microbiol (2012) 2:128. doi:10.3389/fcimb.2012.00128
166. Bouvet JP, Decroix N, Pamonsinlapatham P. Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol (2002) 23(4):209-13. doi:10.1016/S1471-4906(02)02186-5
167. Mora JR, Iwata M, Eksteen B, Song SY, Junt T, Senman B, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science (2006) 314(5802):1157-60. doi:10.1126/science.1132742
168. Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, Butcher EC. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol (2003) 170(7):3799-805. doi:10.4049/jimmunol.170.7.3799
169. Kantele A, Savilahti E, Tiimonen H, Iikkanen K, Autio S, Kantele JM. Cutaneous lymphocyte antigen expression on human effector B cells depends on the site and on the nature of antigen encounter. Eur J Immunol (2003) 33(12):3275-83. doi:10.1002/eji.200324311
170. Sundstrom P, Lundin SB, Nilsson LA, Quiding-Jarbrink M. Human IgA-secreting cells induced by intestinal, but not systemic, immunization respond to CCL25 (TECK) and CCL28 (MEC). Eur J Immunol (2008) 38(12):3327-38. doi:10.1002/eji.200838506
171. Salerno-Goncalves R, Sztein MB. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol (2006) 14(12):536-42. doi:10.1016/j.tim.2006.10.004
172. Eloe-Fadrosh EA, McArthur MA, Seekatz AM, Drabek EF, Rasko DA, Sztein MB, et al. Impact of oral typhoid vaccination on the human gut microbiota and correlations with S. Typhi-specific immunological responses. PLoS One (2013) 8(4):e62026. doi:10.1371/journal.pone.0062026
173. Cohen JJ. Programmed cell death in the immune system. Adv Immunol (1991) 50:55-85. doi:10.1016/S0065-2776(08)60822-6
174. Golstein P, Ojcius DM, Young JD. Cell death mechanisms and the immune system. Immunol Rev (1991) 121:29-65. doi:10.1111/j.1600-065X.1991.tb00822.x
175. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 26(4):239-57. doi:10.1038/bjc.1972.33
176. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol (1996) 14:207-32. doi:10.1146/annurev.immunol.14.1.207
177. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (1994) 91(11):4930-4. doi:10.1073/pnas.91.11.4930
178. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 22:745-63. doi:10.1146/annurev.immunol.22.012703.104702
179. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 401(6754):708-12. doi:10.1038/44385
180. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 204(6):1405-16. doi:10.1084/jem.20062363
181. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 281(1-2):65-78. doi:10.1016/S0022-1759(03)00265-5
182. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 107(12):4781-9. doi:10.1182/blood-2005-12-4818
183. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L, et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol (2010) 40(8):2211-20. doi:10.1002/eji.201040455
184. Qiu Z, Zhang M, Zhu Y, Zheng F, Lu P, Liu H, et al. Multifunctional CD4 T cell responses in patients with active tuberculosis. Sci Rep (2012) 2:216. doi:10.1038/srep00216
185. Johanns TM, Ertelt JM, Rowe JH, Way SS. Regulatory T cell suppressive potency dictates the balance between bacterial proliferation and clearance during persistent Salmonella infection. PLoS Pathog (2010) 6(8):e1001043. doi:10.1371/journal.ppat.1001043
186. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol (2009) 21(10):1105-11. doi:10.1093/intimm/dxp095
187. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity (2013) 38(2):373-83. doi:10.1016/j.immuni.2012.10.021
188. Ergin A, Syrbe U, Scheer R, Thiel A, Adam T, Bussow K, et al. Impaired peripheral Th1 CD4+ T cell response to Escherichia coli proteins in patients with Crohn's disease and ankylosing spondylitis. J Clin Immunol (2011) 31(6):998-1009. doi:10.1007/s10875-011-9575-x
189. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut (1996) 38(3):365-75. doi:10.1136/gut.38.3.365
190. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell (2014) 157(1):121-41. doi:10.1016/j.cell.2014.03.011
191. Nyirenda TS, Seeley AE, Mandala WL, Drayson MT, MacLennan CA. Early interferon-gamma production in human lymphocyte subsets in response to nontyphoidal Salmonella demonstrates inherent capacity in innate cells. PLoS One (2010) 5(10):e13667. doi:10.1371/journal.pone.0013667
192. Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood (2011) 117(4):1250-9. doi:10.1182/blood-2010-08-303339
193. Le Bourhis L, Guerri L, Dusseaux M, Martin E, Soudais C, Lantz O. Mucosal-associated invariant T cells: unconventional development and function. Trends Immunol (2011) 32(5):212-8. doi:10.1016/j.it.2011.02.005
194. Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, Matsunaga T, et al. Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation. Cell Stem Cell (2013) 12(5):546-58. doi:10.1016/j.stem.2013.03.001
195. Cosgrove C, Ussher JE, Rauch A, Gartner K, Kurioka A, Huhn MH, et al. Early and nonreversible decrease of CD161++/MAIT cells in HIV infection. Blood (2013) 121(6):951-61. doi:10.1182/blood-2012-06-436436
196. Leeansyah E, Ganesh A, Quigley MF, Sonnerborg A, Andersson J, Hunt PW, et al. Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood (2013) 121(7):1124-35. doi:10.1182/blood-2012-07-445429
197. Sundquist M, Rydstrom A, Wick MJ. Immunity to Salmonella from a dendritic point of view. Cell Microbiol (2004) 6(1):1-11. doi:10.1046/j.1462-5822.2003.00336.x
198. Segura E, Amigorena S. Cross-presentation by human dendritic cell subsets. Immunol Lett (2014) 158(1-2):73-8. doi:10.1016/j.imlet.2013.12.001
199. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 392(6671):86-9. doi:10.1038/32183
200. Fehres CM, Unger WW, Garcia-Vallejo JJ, van Kooyk Y. Understanding the biology of antigen cross-presentation for the design of vaccines against cancer. Front Immunol (2014) 5:149. doi:10.3389/fimmu.2014.00149
201. Salerno-Goncalves R, Sztein MB. Priming of Salmonella enterica serovar Typhi-specific CD8(+) T cells by suicide dendritic cell cross-presentation in humans. PLoS One (2009) 4(6):e5879. doi:10.1371/journal.pone.0005879
202. Mastroeni P, Harrison JA, Robinson JH, Clare S, Khan S, Maskell DJ, et al. Interleukin-12 is required for control of the growth of attenuated aromatic-compound-dependent salmonellae in BALB/c mice: role of gamma interferon and macrophage activation. Infect Immun (1998) 66(10):4767-76.
203. Hess J, Ladel C, Miko D, Kaufmann SH. Salmonella typhimurium aroA-infection in gene-targeted immunodeficient mice: major role of CD4+ TCR-alpha beta cells and IFN-gamma in bacterial clearance independent of intracellular location. J Immunol (1996) 156(9):3321-6.
204. Brandtzaeg P, Farstad IN, Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today (1999) 20(6):267-77. doi:10.1016/S0167-5699(99)01468-1
205. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol (1999) 72:209-53. doi:10.1016/S0065-2776(08)60022-X
206. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med (2000) 192(5):761-8. doi:10.1084/jem.192.5.761
207. Hamann A, Andrew DP, Jablonski-Westrich D, Holzmann B, Butcher EC. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol (1994) 152(7):3282-93.
208. Kantele A, Zivny J, Hakkinen M, Elson CO, Mestecky J. Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. J Immunol (1999) 162(9):5173-7.
209. Svensson M, Marsal J, Ericsson A, Carramolino L, Broden T, Marquez G, et al. CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest (2002) 110(8):1113-21. doi:10.1172/JCI0215988
210. Agace WW, Higgins JM, Sadasivan B, Brenner MB, Parker CM. T-lymphocyte-epithelial-cell interactions: integrin alpha(E)(CD103)beta(7), LEEP-CAM and chemokines. Curr Opin Cell Biol (2000) 12(5):563-8. doi:10.1016/S0955-0674(00)00132-0
211. Ferreira RB, Antunes LC, Finlay BB. Should the human microbiome be considered when developing vaccines? PLoS Pathog (2010) 6(11):e1001190. doi:10.1371/journal.ppat.1001190
212. John TJ. Experience with poliovaccines in the control of poliomyelitis in India. Public Health Rev (1993) 21(1-2):83-90.
213. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis (1991) 13(5):926-39. doi:10.1093/clinids/13.5.926
214. Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego P, et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis (1999) 180(5):1709-12. doi:10.1086/315051
215. Lopman BA, Pitzer VE, Sarkar R, Gladstone B, Patel M, Glasser J, et al. Understanding reduced rotavirus vaccine efficacy in low socio-economic settings. PLoS One (2012) 7(8):e41720. doi:10.1371/journal.pone.0041720
216. Cooper PJ, Chico ME, Losonsky G, Sandoval C, Espinel I, Sridhara R, et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis (2000) 182(4):1199-206. doi:10.1086/315837
217. Muhsen K, Pasetti MF, Reymann MK, Graham DY, Levine MM. Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive U.S. adults with attenuated Salmonella typhi oral vaccine CVD 908-htrA. J Infect Dis (2014) 209(9):1452-8. doi:10.1093/infdis/jit625
218. Bhan MK, Bahl R, Sazawal S, Sinha A, Kumar R, Mahalanabis D, et al. Association between Helicobacter pylori infection and increased risk of typhoid fever. J Infect Dis (2002) 186(12):1857-60. doi:10.1086/345762
219. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med (2002) 347(15):1175-86. doi:10.1056/NEJMra020542
220. Benyacoub J, Rochat F, Saudan KY, Rochat I, Antille N, Cherbut C, et al. Feeding a diet containing a fructooligosaccharide mix can enhance Salmonella vaccine efficacy in mice. J Nutr (2008) 138(1):123-9.
221. Fang H, Elina T, Heikki A, Seppo S. Modulation of humoral immune response through probiotic intake. FEMS Immunol Med Microbiol (2000) 29(1):47-52. doi:10.1111/j.1574-695X.2000.tb01504.x
222. Pakkanen SH, Kantele JM, Kantele A. Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. Vaccine (2012) 30(42):6047-53. doi:10.1016/j.vaccine.2012.07.051
223. Pakkanen SH, Kantele JM, Kantele A. Cross-reactive immune response induced by the Vi capsular polysaccharide typhoid vaccine against Salmonella Paratyphi strains. Scand J Immunol (2014) 79(3):222-9. doi:10.1111/sji.12151
224. Kantele A, Pakkanen SH, Siitonen A, Karttunen R, Kantele JM. Live oral typhoid vaccine Salmonella Typhi Ty21a -a surrogate vaccine against non-typhoid salmonella? Vaccine (2012) 30(50):7238-45. doi:10.1016/j.vaccine.2012.10.002
225. Pakkanen SH, Kantele JM, Herzog C, Kantele A. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid salmonellae. Vaccine (2014) 32(5):544-51. doi:10.1016/j.vaccine.2013.12.001
226. Charles RC, Sheikh A, Krastins B, Harris JB, Bhuiyan MS, LaRocque RC, et al. Characterization of anti-Salmonella enterica serotype Typhi antibody responses in bacteremic Bangladeshi patients by an immunoaffinity proteomics-based technology. Clin Vaccine Immunol (2010) 17(8):1188-95. doi:10.1128/CVI.00104-10
227. Liang L, Juarez S, Nga TV, Dunstan S, Nakajima-Sasaki R, Davies DH, et al. Immune profiling with a Salmonella Typhi antigen microarray identifies new diagnostic biomarkers of human typhoid. Sci Rep (2013) 3:1043. doi:10.1038/srep01043
228. Thompson LJ, Dunstan SJ, Dolecek C, Perkins T, House D, Dougan G, et al. Transcriptional response in the peripheral blood of patients infected with Salmonella enterica serovar Typhi. Proc Natl Acad Sci U S A (2009) 106(52):22433-8. doi:10.1073/pnas.0912386106
229. Lee SJ, Liang L, Juarez S, Nanton MR, Gondwe EN, Msefula CL, et al. Identification of a common immune signature in murine and human systemic salmonellosis. Proc Natl Acad Sci U S A (2012) 109(13):4998-5003. doi:10.1073/pnas.1111413109
230. Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem (2009) 81(16):6813-22. doi:10.1021/ac901049w
231. Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (2011) 332(6030):687-96. doi:10.1126/science.1198704
232. Bjornson ZB, Nolan GP, Fantl WJ. Single-cell mass cytometry for analysis of immune system functional states. Curr Opin Immunol (2013) 25(4):484-94. doi:10.1016/j.coi.2013.07.004